Back to Blog

Medical Cannabis and PTSD

Post-traumatic stress disorder (PTSD) is a debilitating condition affecting millions worldwide. It is a mental health disorder that can develop after experiencing or witnessing a traumatic event. The symptoms of PTSD can be severe and include flashbacks, nightmares, hypervigilance, and anxiety. The coexistence of PTSD with other mental health conditions such as anxiety disorders, depression, insomnia, and substance use disorders makes treatment even more challenging.

Psychotherapy and medications such as antidepressants, antianxiety medications, and antipsychotics are the mainstay treatments for PTSD. These treatments might not always work and could have significant side effects, especially if more than one medication is taken at a time. People with PTSD are often desperate for a treatment that works well and has few side effects. Some people with PTSD may have discovered that cannabis reduces nightmares, promotes sleep, and calms anxiety and irritability.

The endocannabinoid system (ECS) is a biological system that plays a crucial role in regulating various physiological processes, including mood, stress response, and memory. The ECS is activated by cannabinoids, which can help to modulate the stress response and reduce anxiety.

As the number of veterans suffering from PTSD has greatly increased over the past few decades, understanding how cannabis may benefit individuals with this condition is an important area of research. The amygdala in the brain, which controls anxiety, fear memories, and emotional responses to stress, has been found to have high levels of cannabinoid receptor expression. A well-functioning ECS must exist in order to have an adaptive response to fear and to the associated traumatic memories.

Although published research on the use of cannabis for PTSD is limited, there are some studies to suggest that medical cannabis may be helpful in managing PTSD symptoms.

A randomized, double-blind, placebo crossover study from Canada found that nabilone, a synthetic THC, dramatically reduced the severity and frequency of nightmares and improved general well-being in a small sample of military veterans with treatment-resistant PTSD.In a study published in the Journal of Psychoactive Drugs, 75% of participants with PTSD reported a decrease in symptoms after using medical cannabis.

According to preclinical studies, CBD may inhibit the formation, expression, and reconsolidation of fear memories. The effects of CBD on PTSD patients have only been studied in a small number of human trials, which lack high-quality evidence and call for more research. However, CBD has also been shown to have anxiolytic effects, which could help to alleviate the anxiety and hypervigilance associated with PTSD.

Even though cannabis is becoming more recognized as a potential treatment for PTSD, the concept of receptor downregulation with THC use is critical for patients to understand. Keep in mind that prolonged, heavy use of cannabis with a high THC contentwill reduce the number of cannabinoid receptors, which will eventually cause tolerance and a loss of effectiveness. Cannabis with a high THC content must be used with caution by patients with PTSD to avoid tolerance and maximize effectiveness.

Pro-tip for THC:

• Use lowest amount of THC possible for symptom management
• Co-administer CBD
• Micro-dose THC using vaporizer, avoid smoking cannabis
• Take 1-2-week cannabis holiday as needed

Learn More: Dosing Titration

It’s important to note that while medical cannabis may be a potential treatment option for PTSD, it is not a cure for the condition. PTSD is a complex disorder that requires a comprehensive treatment approach, including therapy, medication, and lifestyle changes.

Medical cannabis should be used in conjunction with other treatments under the guidance of a healthcare professional. Need help connecting with a Healthcare professional for Medical cannabis?

Book an Appointment


References:
Greer, G.R., Grob, C.S., & Halberstadt, A.K. (2014). PTSD symptom reports of patients evaluated for the New Mexico medical cannabis program. Journals of Psychoactive Drugs, 46 (1), 73-77.
Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585-588.
Parker, L.A., Rock, E.M., & Mechoulam, R. (2022). CBD: what does the science say? Massachusetts Institute of Technology.

Previous Article
Softgels: Frequently Asked Questions
If you’re new to Softgels, we’ve prepared a list of frequently asked questions below to help you get familiar with our cannabis "capsules". "Are Softgels right for me?" Softgels are an ideal medical cannabis option for patients looking for consistent, pre-measured dosing in a non-combustible, smoke-free format. They’re discreet, convenient and easy-to-swallow. Softgels are also typically cost-effective, with most bottles containing 30 softgels and others containing 15. "What are the potencies of softgels available to Starseed patients?" Starseed offers Softgels in various CBD, balanced and THC profiles to meet the needs of all patients. You'll find the CBD and THC potencies listed within each product card on our shop. For Softgels, potencies are measured by each individual softgel, not the entire contents of the bottle, so that you know exactly how much you are taking per each dosage (see portion outlined in red below). "Which Softgel is best for me?" If you’re already familiar with cannabis oil or oral sprays, we recommend choosing a Softgel that most closely mirrors the formulation of your preferred oil. For example; if you prefer a Star-1 cannabis oil, then choose a Star-1 softgel! Currently, Softgels are offered in 4 separate brands that all provide their own unique benefits. You'll find Irwin Naturals, CB4 Relief Softgels, Redecan and Starseed-branded softgels all listed on our shop. If you're unsure, consult your physician or healthcare professional to determine whether Softgels may be right for you, and the dose that best fits your treatment plan. We always recommend patients “start low, and go slow.” "What are Starseed Softgels made of?" Our Softgels are made of a few simple ingredients, including gelatin, coconut MCT oil and, of course, cannabis!
Next Article
Fibromyalgia and Endocannabinoid Deficiency Theory
Fibromyalgia is a chronic condition that causes widespread pain, tenderness, and fatigue. It is a relatively common condition, affecting 2% of Canadians. Despite being a relatively common condition, the causes of fibromyalgia are still not well understood, and treatment options are limited. Recently, researchers have been exploring the role of the endocannabinoid system in the development and management of fibromyalgia. The endocannabinoid system is a complex network of receptors and chemicals that play a role in regulating pain, mood, and other physiological processes. One theory is that endocannabinoid deficiency may play a role in the development of fibromyalgia. The endocannabinoid system helps regulate pain perception, and a deficiency in this system could lead to an increase in sensitivity to pain. This could help explain why people with fibromyalgia experience pain even in the absence of any obvious physical cause. There is evidence to support the theory that endocannabinoid deficiency may play a role in fibromyalgia. Research has shown that people with fibromyalgia have lower levels of endocannabinoids, such as anandamide, compared to healthy individuals. This suggests that an endocannabinoid deficiency may be a contributing factor in the development of fibromyalgia. To address endocannabinoid deficiency in fibromyalgia, some patients have turned to medical cannabis. Medical cannabis contains compounds called cannabinoids, which can interact with the endocannabinoid system and help regulate pain perception. In some cases, medical cannabis has been shown to be an effective treatment for fibromyalgia, helping to reduce pain, improve sleep, and increase overall quality of life. It is important to note that medical cannabis is not a cure for fibromyalgia and that further research is needed to fully understand its potential as a treatment option. However, for some patients with fibromyalgia, medical cannabis may offer a much-needed alternative to traditional pain management methods that may be less effective or carry more side effects. Learn more about Chronic Pain In conclusion, the endocannabinoid system may play a role in the development and management of fibromyalgia. Endocannabinoid deficiency may contribute to the pain and tenderness experienced by people with this condition, and medical cannabis may offer a promising alternative for those who are struggling to find effective treatment. However, more research is needed to fully understand the relationship between endocannabinoids and fibromyalgia, and to determine the best ways to address endocannabinoid deficiency in this population. Need help getting a Medical Cannabis Treatment Plan for Fibromyalgia? Book an appointment here. References: Benedict, G., Sabbagh, A., & Conermann. (2022). Medical cannabis used as an alternative treatment for chronic pain demonstrates reduction in chronic opioid use – a prospective study. Pain Physician Journal, 25, E113-E119. Retrieved from https://www.painphysicianjournal.com/current/pdf?article=NzQwOA%3D%3D. Johal, H. et al. (2020). Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 13, 1-13. https://doi.org/10.1177/1179544120906461 Herman, J., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., et al. (2020). Cannabinoids in chronic non-cancer pain: a systematic review and meta-analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 13, 1-13. Retrieved from https://journals.sagepub.com/doi/pdf/10.1177/1179544120906461. Russo, E. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1(1), 2016.

Loading